University of Maryland Medical Center

U of Maryland School of Medicine Researchers Identify Potent Antibody Cocktail to Treat COVID-19

Publication highlights process for yielding array of human antibodies that target protein on virus

Newswise — Researchers at the University of Maryland School of Medicine (UMSOM) evaluated several human antibodies to determine the most potent combination to be mixed in a cocktail and used as a promising anti-viral therapy against the virus that causes COVID-19. Their research, conducted in collaboration with scientists at Regeneron Pharmaceuticals, was published Monday in the journal Science. The study demonstrates the rapid process of isolating, testing and mass-producing antibody therapies against any infectious disease by using both genetically engineered mice and plasma from recovered COVID-19 patients.

The antibody cocktail evaluated by UMSOM researchers will be used to treat COVID-19 patients in a clinical trial that was launched last week. The study was funded by Regeneron, a biotechnology company based in Tarrytown, New York.

Antibodies are proteins the immune system naturally makes in response to foreign invaders like viruses and bacteria. Antibody therapies were first tried in the late 19th century when researchers used a serum derived from the blood of infected animals to treat diphtheria.

To produce the so-called monoclonal antibodies for an antibody cocktail to fight COVID-19, the researchers first needed to identify which antibodies fight the novel coronavirus most effectively.

This involved determining which antibodies could bind most effectively to the spike protein found on the surface of SARS-CoV-2, the virus that causes COVID-19. The Regeneron team evaluated thousands of human antibodies from plasma donations from recovered COVID-19 patients. They also generated antibodies from mice genetically engineered to produce human antibodies when infected with the virus.

"The ability of the research team to rapidly derive antibodies using these two methods enabled us screen their selected antibodies against live virus to determine which had the strongest anti-viral effects," said study co-author Matthew Frieman, PhD, Associate Professor of Microbiology and Immunology at the University of Maryland School of Medicine. He has been studying coronaviruses for the past 16 years and has been carefully studying SARS-CoV-2 in his secure laboratory since February.

Dr. Frieman and his UMSOM colleagues evaluated four of the most potent antibodies for to determine the potential of each one to neutralize the SARS-CoV-2 virus. They identified the two that would form the most powerful mix when used in combination.

"An important goal of this research was to evaluate the most potent antibodies that bind to different molecules in the spike protein so they could be mixed together as a treatment," said study co-author Stuart Weston, PhD, a post-doctoral research fellow in the Department of Microbiology and Immunology.

The cocktail containing the two antibodies is now being tested in a new clinical trial sponsored by Regeneron that will investigate whether the therapy can improve the outcomes of COVID-19 patients (both those who are hospitalized and those who are not). It will also be tested as a preventive therapy in those who are healthy but at high risk of getting sick because they work in a healthcare setting or have been exposed to an infected person.

"Our School of Medicine researchers continue to provide vital advances on all fronts to help fight the COVID-19 pandemic and ultimately save lives," said Dean E. Albert Reece, MD, PhD, MBA, who is also Executive Vice President for Medical Affairs, UM Baltimore, and the John Z. and Akiko K. Bowers Distinguished Professor, University of Maryland School of Medicine. "This particular research not only contributes to a potential new therapy against COVID-19 but could have broader implications in terms of the development of monoclonal antibody therapies for other diseases."

###

About the University of Maryland School of Medicine

Now in its third century, the University of Maryland School of Medicine was chartered in 1807 as the first public medical school in the United States. It continues today as one of the fastest growing, top-tier biomedical research enterprises in the world -- with 45 academic departments, centers, institutes, and programs; and a faculty of more than 3,000 physicians, scientists, and allied health professionals, including members of the National Academy of Medicine and the National Academy of Sciences, and a distinguished two-time winner of the Albert E. Lasker Award in Medical Research. With an operating budget of more than $1.2 billion, the School of Medicine works closely in partnership with the University of Maryland Medical Center and Medical System to provide research-intensive, academic and clinically based care for nearly 2 million patients each year. The School of Medicine has more than $540 million in extramural funding, with most of its academic departments highly ranked among all medical schools in the nation in research funding. As one of the seven professional schools that make up the University of Maryland, Baltimore campus, the School of Medicine has a total population of nearly 9,000 faculty and staff, including 2,500 student trainees, residents, and fellows. The combined School of Medicine and Medical System ("University of Maryland Medicine") has an annual budget of nearly $6 billion and an economic impact more than $15 billion on the state and local community. The School of Medicine faculty, which ranks as the 8th highest among public medical schools in research productivity, is an innovator in translational medicine, with 600 active patents and 24 start-up companies. The School of Medicine works locally, nationally, and globally, with research and treatment facilities in 36 countries around the world. Visit medschool.umaryland.edu

SEE ORIGINAL STUDY




Filters close

Showing results

1120 of 2911
Newswise: Americans actively engaging in collectivism as financial buoy, experts say
Released: 13-Aug-2020 11:25 AM EDT
Americans actively engaging in collectivism as financial buoy, experts say
University of Notre Dame

Karen Richman, University of Notre Dame director of undergraduate studies at the Institute for Latino Studies, and her colleague, found that many people in the U.S. are relying on informal networks of family and friends to stay afloat in a recent study.

Newswise: 240116_web.jpg
Released: 13-Aug-2020 11:20 AM EDT
Researchers identify a protein that may help SARS-CoV-2 spread rapidly through cells
Colorado State University

Eric Ross and Sean Cascarina, biochemistry and molecular biology researchers at Colorado State University, have released a research paper identifying a protein encoded by SARS-CoV-2, the virus that causes COVID-19, that may be associated with the quick spread of the virus through cells in the human body.

Newswise: 240119_web.jpg
Released: 13-Aug-2020 11:05 AM EDT
Public health consequences of policing homelessness
University of Colorado Denver

Two weeks ago, Colorado State Patrol troopers began clearing out nearly 200 residents from homeless encampments that surround the Colorado Capitol.

Released: 13-Aug-2020 10:35 AM EDT
Age discrimination seen @Twitter during #COVID19 pandemic
University of Michigan

The COVID-19 pandemic has created a perfect storm for age discrimination on social media.

Released: 13-Aug-2020 10:15 AM EDT
New COVID-19 Model Reveals Need for Better Travel Restriction Implementation
Rensselaer Polytechnic Institute (RPI)

More strategic and coordinated travel restrictions could have reduced the spread of COVID-19 in the early stages of the pandemic, data confirms. The conclusion, available in preprint on MedRxiv, an online repository of papers that have been screened but not peer reviewed, stems from new modeling conducted by a multidisciplinary team of scientists and engineers at Rensselaer Polytechnic Institute.

Released: 13-Aug-2020 10:05 AM EDT
Four National Organizations Provide Guidance on Maintaining Essential Operations as COVID-19 Pandemic Continues
American Society of Anesthesiologists (ASA)

The recent resurgence of Coronavirus Disease 2019 (COVID-19) has many states near or at bed and intensive care unit (ICU) capacity, and health care facilities’ ability to meet the ongoing needs of surgical patients may be stressed by new influxes of COVID-19 patients admitted to health care facilities. To ensure health care organizations, physicians, and nurses remain prepared to meet these demands to care for patients who undergo recommended essential operations, the American College of Surgeons (ACS), American Society of Anesthesiologists (ASA), Association of periOperative Registered Nurses (AORN) and American Hospital Association (AHA) have developed a Joint Statement: Roadmap for Maintaining Essential Surgery During COVID-19 Pandemic. This joint statement provides a list of principles and considerations to guide physicians, nurses, and hospitals and health systems as they provide essential care to their patients and communities. This joint statement builds on the Joint Statement:

Newswise: COVID-19 Vaccine Candidate Tested at University of Kentucky Shows Positive Preclinical Results
Released: 13-Aug-2020 8:50 AM EDT
COVID-19 Vaccine Candidate Tested at University of Kentucky Shows Positive Preclinical Results
University of Kentucky

PDS Biotechnology, a clinical stage immunotherapy company, has announced positive results from preclinical testing conducted at the University of Kentucky College of Medicine of its COVID-19 vaccine candidate, PDS0203.

Released: 13-Aug-2020 8:45 AM EDT
Oxygen Therapy Harms Lung Microbiome in Mice
Michigan Medicine - University of Michigan

New mouse study on the lung microbiome could have implications for treatment of reduced oxygen levels in critically ill patients—including those with COVID-19.

Newswise:Video Embedded slac-scientists-invent-low-cost-emergency-ventilator-and-share-the-design-for-free
VIDEO
Released: 13-Aug-2020 8:45 AM EDT
SLAC scientists invent low-cost emergency ventilator and share the design for free
SLAC National Accelerator Laboratory

Researchers at the Department of Energy’s SLAC National Accelerator Laboratory have invented an emergency ventilator that could help save the lives of patients suffering from COVID-19, the disease caused by novel coronavirus SARS-CoV-2.

Newswise: 240021_web.jpg
Released: 13-Aug-2020 8:35 AM EDT
Scientists identify hundreds of drug candidates to treat COVID-19
University of California, Riverside

Scientists at the University of California, Riverside, have used machine learning to identify hundreds of new potential drugs that could help treat COVID-19, the disease caused by the novel coronavirus, or SARS-CoV-2.


Showing results

1120 of 2911

close
2.45734